These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32410165)

  • 1. Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis.
    Lalezari S; Acquadro M; de Bock E; Lambert J; Simpson ML
    Adv Ther; 2020 Jun; 37(6):2763-2776. PubMed ID: 32410165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII).
    Wells JR; Gater A; Marshall C; Tritton T; Vashi P; Kessabi S
    Patient; 2019 Dec; 12(6):611-619. PubMed ID: 31313270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.
    Chowdary P; Kearney S; Regnault A; Hoxer CS; Yee DL
    Haemophilia; 2016 Jul; 22(4):e267-74. PubMed ID: 27352908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient powered prophylaxis: A 12-month study of individualized prophylaxis in adults with severe haemophilia A.
    Sun HL; McIntosh KA; Squire SJ; Yang M; Bartholomew C; Gue DS; Camp PG; Jackson SC
    Haemophilia; 2017 Nov; 23(6):877-883. PubMed ID: 28851133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A.
    Santagostino E; Kenet G; Fischer K; Biss T; Ahuja S; Steele M
    Haemophilia; 2020 May; 26(3):e55-e65. PubMed ID: 32212300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
    Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
    Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
    Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
    Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study.
    Reding MT; Pabinger I; Holme PA; Poulsen L; Negrier C; Chalasani P; Maas Enriquez M; Wang M; Meijer K; Mancuso ME; Lalezari S
    Haemophilia; 2021 May; 27(3):e347-e356. PubMed ID: 33818853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa.
    Santagostino E; Lentz SR; Busk AK; Regnault A; Iorio A
    Haemophilia; 2014 Jul; 20(4):527-34. PubMed ID: 24471912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia.
    Rentz A; Flood E; Altisent C; Bullinger M; Klamroth R; Garrido RP; Scharrer I; Schramm W; Gorina E;
    Haemophilia; 2008 Sep; 14(5):1023-34. PubMed ID: 18665853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A.
    Mancuso ME; Biss T; Fischer K; Maas Enriquez M; Steele M; Wang M; Tseneklidou-Stoeter D; Ahuja S; Kenet G
    Haemophilia; 2021 May; 27(3):434-444. PubMed ID: 33724632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial.
    Santagostino E; Lalezari S; Reding MT; Ducore J; Ng HJ; Poulsen LH; Michaels LA; Linardi CCG
    Thromb Res; 2019 Nov; 183():13-19. PubMed ID: 31513978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States.
    Thornburg CD; Carpenter S; Zappa S; Munn J; Leissinger C
    Haemophilia; 2012 Jul; 18(4):568-74. PubMed ID: 22335526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study.
    Stasyshyn O; Antunes S; Mamonov V; Ye X; Epstein J; Xiong Y; Tangada S
    Haemophilia; 2014 Sep; 20(5):644-50. PubMed ID: 24589084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A.
    Crivianu-Gaita V; Rivard GE; Carcao M; Teitel J; St-Louis J; Blanchette V; Pullenayegum E; Abad A; Feldman BM
    Haemophilia; 2016 Sep; 22(5):e401-5. PubMed ID: 27481574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires.
    Astermark J; Hermans C; Ezzalfani M; Aballéa S; Santagostino E; Hakimi Z; Nazir J
    Haemophilia; 2022 Jan; 28(1):18-26. PubMed ID: 34761474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study.
    Oldenburg J; Tran H; Peyvandi F; Núñez R; Trask P; Chebon S; Mahlangu JN; Lehle M; Jiménez-Yuste V; von Mackensen S
    Haemophilia; 2021 May; 27(3):398-407. PubMed ID: 33576546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.
    Saxena K; Lalezari S; Oldenburg J; Tseneklidou-Stoeter D; Beckmann H; Yoon M; Maas Enriquez M
    Haemophilia; 2016 Sep; 22(5):706-12. PubMed ID: 27339736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric evaluation of a patient-reported symptom assessment tool for adults with haemophilia (the HAEMO-SYM).
    Rentz A; Flood E; Butler R; Christie B; Giangrande P; McCusker P; Wasserman J; Gorina E
    Haemophilia; 2009 Sep; 15(5):1039-47. PubMed ID: 19515029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).
    Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B;
    Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.